BioSpace News Archive

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced, following publication of promising data from a Phase 2b Dupuytren’s trial in the June 2022 issues of The Lancet Rheumatology, that 180 Life Sciences has initiated preliminary consultations with regulatory agencies in both the UK and USA, with the assistance of Kinexum, the Company’s regulatory advisor.

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced it has signed a collaboration agreement with Polyrizon Ltd., a biotech company focused on the development of innovative medical device hydrogels delivered in the form of nasal sprays (“Polyrizon”).

SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced its participation at the Large Animal Genetic Engineering Summit (LAGE) taking place June 5-8, 2022, in Park City, Utah.

Acquisition strengthens Regeneron’s innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.

In medical news, Functional Fluidics today announces that abstracts related to their red blood cell biomarker used in sickle cell disease management will be presented during the Foundation for Sickle Cell Disease Research’s (FSCDR) 16th Annual SCD Research and Educational Symposium in Florida from June 10th - June 12th, 2022.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the 2022 ASCO® Annual Meeting taking place June 3 – 7, 2022.

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2022.

DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation: “Like many companies, Dexcom’s Board and management team regularly review opportunities to enhance stockholder value and create benefits for customers, including through mergers and acquisitions.

Champions Oncology, Inc. and Cyclica Inc. announced today a therapeutic development partnership.